WO2001036674A3 - Diagnostic methods for detection of prostate disorders - Google Patents

Diagnostic methods for detection of prostate disorders Download PDF

Info

Publication number
WO2001036674A3
WO2001036674A3 PCT/GB2000/004267 GB0004267W WO0136674A3 WO 2001036674 A3 WO2001036674 A3 WO 2001036674A3 GB 0004267 W GB0004267 W GB 0004267W WO 0136674 A3 WO0136674 A3 WO 0136674A3
Authority
WO
WIPO (PCT)
Prior art keywords
detection
markers
prostate disorders
diagnostic methods
prostate
Prior art date
Application number
PCT/GB2000/004267
Other languages
French (fr)
Other versions
WO2001036674A2 (en
Inventor
John Henry Bull
Gillian Ellison
Lynn Dora Paskins
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
John Henry Bull
Gillian Ellison
Lynn Dora Paskins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, John Henry Bull, Gillian Ellison, Lynn Dora Paskins filed Critical Astrazeneca Ab
Priority to AU11631/01A priority Critical patent/AU1163101A/en
Publication of WO2001036674A2 publication Critical patent/WO2001036674A2/en
Publication of WO2001036674A3 publication Critical patent/WO2001036674A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention derives from the identification of 26 gene transcripts (Markers) that exhibit aberrant expression levels in prostate disorder tissues. The invention therefore relates to diagnostic techniques for the detection of human prostate disorders, such as cancer, by detecting one or more of these Markers, intermediates, precursors or products (mRNA, cDNA, genomic DNA, or protein). The invention is also directed to methods for identifying modulators of prostate disorders, which modulators, such as chemical compounds, antisense molecules and antibodies interact with and modulate any one of the Markers identified.
PCT/GB2000/004267 1999-11-13 2000-11-08 Diagnostic methods for detection of prostate disorders WO2001036674A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU11631/01A AU1163101A (en) 1999-11-13 2000-11-08 Diagnostic methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9926805.4 1999-11-13
GBGB9926805.4A GB9926805D0 (en) 1999-11-13 1999-11-13 Diagnostic methods

Publications (2)

Publication Number Publication Date
WO2001036674A2 WO2001036674A2 (en) 2001-05-25
WO2001036674A3 true WO2001036674A3 (en) 2002-03-28

Family

ID=10864423

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/004267 WO2001036674A2 (en) 1999-11-13 2000-11-08 Diagnostic methods for detection of prostate disorders

Country Status (3)

Country Link
AU (1) AU1163101A (en)
GB (1) GB9926805D0 (en)
WO (1) WO2001036674A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1265918A1 (en) * 2000-03-15 2002-12-18 Incyte Genomics, Inc. Human immune response proteins
WO2001096389A2 (en) * 2000-06-09 2001-12-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
CN1554025A (en) * 2001-03-12 2004-12-08 Īŵ���ɷ����޹�˾ Cell-based detection and differentiation of disease states
US6537811B1 (en) 2001-08-01 2003-03-25 Isis Pharmaceuticals, Inc. Antisense inhibition of SAP-1 expression
DE60225046T2 (en) * 2001-11-27 2009-07-09 Nexyte Ab PRODUCTION OF EUKARYONTIC PROTEINS AND NUCLEIC ACID MOLECULES IN C. ELEGANS
AU2003210554A1 (en) * 2002-01-18 2003-09-02 Millennium Pharmaceuticals, Inc. Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo
US20050037447A1 (en) * 2003-07-08 2005-02-17 Yong-Chuan Wong Protein markers for human benign prostatic hyperplasia (BPH)
AU2011282892B2 (en) 2010-07-27 2015-07-16 Mdxhealth Sa Method for using gene expression to determine prognosis of prostate cancer
CN112592974A (en) * 2019-12-13 2021-04-02 四川省人民医院 Diagnostic agent, kit and use for diagnosing or aiding in the diagnosis of renal insufficiency or renal injury

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037811A1 (en) * 1998-01-21 1999-07-29 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
WO1999049083A1 (en) * 1998-03-24 1999-09-30 Urocor, Inc. Diagnosis of disease state using mrna profiles in peripheral leukocytes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037811A1 (en) * 1998-01-21 1999-07-29 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
WO1999049083A1 (en) * 1998-03-24 1999-09-30 Urocor, Inc. Diagnosis of disease state using mrna profiles in peripheral leukocytes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. SHEN ET AL.: "Androgen regulation of the human pseudoautosomal gene MIC2, a potential marker for prostate cancer.", MOLECULAR CARCINOGENESIS, vol. 23, no. 1, September 1998 (1998-09-01), USA, pages 13 - 19, XP001015750 *
M. BUSSEMAKERS ET AL.: "DD3: a new prostate-specific marker, overexpressed in prostatic tumors.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 87, March 1996 (1996-03-01), Philadelphia, PA, USA, pages 515, XP002074304 *
R. THWEATT ET AL.: "A novel gene encoding a smooth muscle protein is overexpressed in senescent human fibroblasts.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 187, no. 1, 31 August 1992 (1992-08-31), San Diego, CA, USA, pages 1 - 7, XP002175119 *

Also Published As

Publication number Publication date
GB9926805D0 (en) 2000-01-12
AU1163101A (en) 2001-05-30
WO2001036674A2 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
Chen et al. Expression of neural BC200 RNA in human tumours
ATE331811T1 (en) METHOD FOR DETECTING NUCLEIC ACIDS INdicative of CANCER
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2002071928A3 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
Tokumaru et al. The role of PGP9. 5 as a tumor suppressor gene in human cancer
WO2003000012A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
WO1999055858A3 (en) Human nucleic acid sequences obtained from pancreas tumor tissue
WO2001036674A3 (en) Diagnostic methods for detection of prostate disorders
WO2002063005A3 (en) Lipid-associated molecules
WO2009027978A8 (en) NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS
WO2004005530A3 (en) Compositions and methods for treatment and detection of multiple cancers
WO1999046374A3 (en) Human nucleic acid sequences from prostate tumour tissue
WO2003008578A3 (en) Reagents and methods for identifying gene targets for treating cancer
WO2006066154A3 (en) Casein kinase 2 antisense therapy
WO2003016497A3 (en) Molecules for disease detection and treatment
WO2003020887A3 (en) Gene identification
WO1999046375A3 (en) Human nucleic acid sequences from prostate tissue
WO2003070965A3 (en) The eaat2 promoter and uses thereof
WO2003052049A3 (en) Molecules for disease detection and treatment
WO2003037257A3 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
WO2003031595A3 (en) Molecules for disease detection and treatment
WO2003012102A3 (en) Nucleic acids coding for novel hect domain proteins, their diagnostic and therapeutic uses
WO2003012103A3 (en) Nucleic acids coding for novel fbox proteins, their diagnostic and therapeutic uses
WO2002017947A3 (en) Use of t proteins for the differential characterization and treatment of lesions and tumors of the nervous system
WO1999043832A3 (en) Human proteinase molecules

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase